SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of Sufenidone (SC1011)
in patients with IPF, and to provide a new safe and effective treatment option for patients
with IPF. Participants will complete the study including screening period, treating period,
and follow-up period. Investigators will compare the annual rate of decline in FVC to see if
it is an optional new drug. The participants have lung function tests at study visits. The
results of the lung function tests are compared between the SC1011 groups and the placebo
group. The doctors also regularly check the general health of the participants.